Article Details

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $9.13 Consensus Target Price from Brokerages

Retrieved on: 2024-12-11 18:58:19

Tags for this article:

Click the tags to see associated articles and topics

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $9.13 Consensus Target Price from Brokerages. View article details on hiswai:

Excerpt

Vanguard Group Inc. now owns 2,303,648 shares of the company's stock valued at $7,948,000 after acquiring an additional 60,249 shares in the last ...

Article found on: www.defenseworld.net

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo